Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 2
2020 9
2021 9
2022 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean martin petruzzo (97 results)?
Cognitive trajectories in multiple sclerosis: a long-term follow-up study.
Carotenuto A, Costabile T, Pontillo G, Moccia M, Falco F, Petracca M, Petruzzo M, Russo CV, Di Stasi M, Paolella C, Perillo T, Vola EA, Cipullo MB, Cocozza S, Lanzillo R, Brescia Morra V, Saccà F. Carotenuto A, et al. Among authors: petruzzo m. Neurol Sci. 2022 Feb;43(2):1215-1222. doi: 10.1007/s10072-021-05356-2. Epub 2021 Jun 8. Neurol Sci. 2022. PMID: 34105018 Free PMC article.
Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis.
Capasso N, Nozzolillo A, Scalia G, Lanzillo R, Carotenuto A, De Angelis M, Petruzzo M, Saccà F, Russo CV, Brescia Morra V, Moccia M. Capasso N, et al. Among authors: petruzzo m. Mult Scler Relat Disord. 2021 Apr;49:102802. doi: 10.1016/j.msard.2021.102802. Epub 2021 Jan 28. Mult Scler Relat Disord. 2021. PMID: 33556652
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
Clerico M, De Mercanti SF, Signori A, Iudicello M, Cordioli C, Signoriello E, Lus G, Bonavita S, Lavorgna L, Maniscalco GT, Curti E, Lorefice L, Cocco E, Nociti V, Mirabella M, Baroncini D, Mataluni G, Landi D, Petruzzo M, Lanzillo R, Gandoglia I, Laroni A, Frangiamore R, Sartori A, Cavalla P, Costantini G, Sormani MP, Capra R. Clerico M, et al. Among authors: petruzzo m. Neurotherapeutics. 2020 Jan;17(1):200-207. doi: 10.1007/s13311-019-00776-7. Neurotherapeutics. 2020. PMID: 31452081 Free PMC article.
Peripapillary Vessel Density as Early Biomarker in Multiple Sclerosis.
Cennamo G, Carotenuto A, Montorio D, Petracca M, Moccia M, Melenzane A, Tranfa F, Lamberti A, Spiezia AL, Servillo G, De Angelis M, Petruzzo M, Criscuolo C, Lanzillo R, Brescia Morra V. Cennamo G, et al. Among authors: petruzzo m. Front Neurol. 2020 Jun 17;11:542. doi: 10.3389/fneur.2020.00542. eCollection 2020. Front Neurol. 2020. PMID: 32625163 Free PMC article.
Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study.
Lanzillo R, Carotenuto A, Signoriello E, Iodice R, Miele G, Bisecco A, Maniscalco GT, Sinisi L, Romano F, Di Gregorio M, Lavorgna L, Trojsi F, Moccia M, Fratta M, Capasso N, Dubbioso R, Petracca M, Spiezia AL, Gallo A, Petruzzo M, De Angelis M, Bonavita S, Lus G, Tedeschi G, Brescia Morra V. Lanzillo R, et al. Among authors: petruzzo m. J Clin Med. 2022 Apr 7;11(8):2081. doi: 10.3390/jcm11082081. J Clin Med. 2022. PMID: 35456175 Free PMC article.
COVID-19 pandemic and mental distress in multiple sclerosis: Implications for clinical management.
Costabile T, Carotenuto A, Lavorgna L, Borriello G, Moiola L, Inglese M, Petruzzo M, Trojsi F, Ianniello A, Nozzolillo A, Cellerino M, Boffa G, Rosa L, Servillo G, Moccia M, Bonavita S, Filippi M, Lanzillo R, Brescia Morra V, Petracca M. Costabile T, et al. Among authors: petruzzo m. Eur J Neurol. 2021 Oct;28(10):3375-3383. doi: 10.1111/ene.14580. Epub 2020 Nov 3. Eur J Neurol. 2021. PMID: 33043560 Free PMC article.
21 results